文献速递神经肿瘤脑血管病外科

微导管递送神经治疗药物:与间充质干细胞的兼容性

Microcatheter delivery of neurotherapeutics: compatibility with mesenchymal stem cells.
PubMed 文献 · J Neurosurg · 2019-09-06

本研究评估装载溶瘤腺病毒Delta-24-RGD的骨髓间充质干细胞(BM-hMSC-Delta-24)经4种常用微导管及神经介入药物后的细胞计数与活性。结果显示不同导管、注射速度、导管形状及与造影剂、维拉帕米、肝素混合均不影响细胞计数和活性,且抗胶质瘤活性维持。

要点

  • BM-hMSC-Delta-24经Marathon、Echelon-14、Marksman、SL-10微导管后细胞计数与活性无显著差异。
  • 注射速度从1.0 ml/min增至73.2 ml/min或导管由直变弯不显著降低细胞计数与活性。
  • 与临床浓度Omnipaque、维拉帕米、肝素混合不改变细胞计数与活性。

核心结论

  • BM-hMSC-Delta-24与多种神经介入常用微导管及药物兼容,可经动脉途径递送干细胞神经治疗药物。

研究设计与样本

  • 体外实验:BM-hMSC经Delta-24-RGD转染后重悬于1%人血清白蛋白,经4种不同内径微导管注射,评估细胞计数与活性。

主要发现

  • 预输注BM-hMSC-Delta-24细胞计数为1.2 × 105 cells/ml,活性98.7%。
  • 经任何微导管输注后细胞计数或活性均无显著差异。
  • 注射速度从1.0 ml/min增至73.2 ml/min或导管形状由直变弯未显著降低细胞计数或活性。
  • 细胞溶液冰上保存至5小时细胞计数和活性保持稳定。
  • Transwell实验显示输注后BM-hMSC-Delta-24的抗胶质瘤活性维持。

临床怎么用

  • commercially available微导管可用于经动脉递送干细胞神经治疗药物,导管配置和注射速度不影响细胞活性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Bone marrow-derived human mesenchymal stem cells (BM-hMSCs) have been used in clinical trials for the treatment of several neurological disorders. MSCs have been explored as a delivery modality for targeted viral therapeutic agents in the treatment of intracranial pathologies. Delta-24-RGD, a tumor-selective oncolytic adenovirus designed to target malignant glioma cells, has been shown to be effective in animal models and in a recent clinical trial. However, the most efficient strategy for delivering oncolytic therapies remains unclear. BM-hMSCs have been shown to home toward glioma xenografts after intracarotid delivery. The feasibility of selective intraarterial infusion of BM-hMSCs loaded with Delta-24-RGD (BM-hMSC-Delta-24) to deliver the virus to the tumor is being investigated. To evaluate the feasibility of endovascular intraarterial delivery, the authors tested in vitro the compatibility of BM-hMSC-Delta-24 with a variety of commercially available, clinically common microcatheters. METHODS: BM-hMSCs were cultured, transfected with Delta-24-RGD, and resuspended in 1% human serum albumin. The solution was then injected via 4 common neuroendovascular microcatheters of different inner diameters (Marathon, Echelon-14, Marksman, and SL-10). Cell count and viability after injection through the microcatheters were assessed, including tests of injection velocity and catheter configuration. Transwell assays were performed with the injected cells to test the efficacy of BM-hMSC-Delta-24 activity against U87 glioma cells. BM-hMSC-Delta-24 compatibility was also tested with common neuroendovascular medications: Omnipaque, verapamil, and heparin. RESULTS: The preinfusion BM-hMSC-Delta-24 cell count was 1.2 × 105 cells/ml, with 98.7% viability. There was no significant difference in postinfusion cell count or viability for any of the catheters. Increasing the injection velocity from 1.0 ml/min to 73.2 ml/min, or modifying the catheter shape from straight to tortuous, did not significantly reduce cell count or viability. Cell count and viability remained stable for up to 5 hours when the cell solution was stored on ice. Mixing BM-hMSC-Delta-24 with clinical concentrations of Omnipaque, verapamil, and heparin prior to infusion did not alter cell count or viability. Transwell experiments demonstrated that the antiglioma activity of BM-hMSC-Delta-24 was maintained after infusion. CONCLUSIONS: BM-hMSC-Delta-24 is compatible with a wide variety of microcatheters and medications commonly used in neuroendovascular therapy. Stem cell viability and viral agent activity do not appear to be affected by catheter configuration or injection velocity. Commercially available microcatheters can be used to deliver stem cell neurotherapeutics via intraarterial routes.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Srinivasan VM, Gumin J, Camstra KM, et al. Microcatheter delivery of neurotherapeutics: compatibility with mesenchymal stem cells. J Neurosurg. 2019. PMID: 31491769. doi:10.3171/2019.6.JNS19327

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。